Investor Polaris Venture Partners V, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Polaris Venture Partners V, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-12-12 13D/A IVVD / Invivyd, Inc. 8,094,512
2023-02-07 13G/A LYRA / Lyra Therapeutics, Inc. 1,423,772 1,423,772
2022-06-24 13D/A ADGI / Adagio Therapeutics Inc 8,531,700 8,531,700
2022-04-26 13D/A ADGI / Adagio Therapeutics Inc 8,531,700 8,531,700
2022-03-30 13D/A ADGI / Adagio Therapeutics Inc 8,531,700 8,531,700
2021-08-20 13D ADGI / Adagio Therapeutics Inc 8,531,700
2021-02-12 13G/A PHR / Phreesia, Inc. 3,214,092 0
2021-02-12 13G LYRA / Lyra Therapeutics, Inc. 1,423,772
2020-02-12 13D/A SELB / Selecta Biosciences Inc 2,779,889 2,789,889
2020-02-12 13G PHR / Phreesia, Inc. 3,214,092
2020-02-12 13G/A KALA / KALA BIO, Inc. 1,890,913 598,620
2020-02-12 13G/A CDLX / Cardlytics, Inc. 2,552,626 9,010
2019-07-17 13D/A XFOR / X4 Pharmaceuticals, Inc. 311,492
2019-07-17 13D/A PULM / Pulmatrix, Inc. 7,510,187 760,851
2019-07-17 13D/A LIFE / aTyr Pharma, Inc. 130,571
2019-02-14 13D/A TTOO / T2 Biosystems, Inc. 2,018,450 1,841,924
2019-02-14 13G CDLX / Cardlytics, Inc. 2,552,626
2019-02-14 13D/A TRVN / Trevena, Inc. 2,669,280 2,053,540
2019-02-14 13D/A GNCA / Genocea Biosciences Inc 1,968,606 1,968,606
2019-02-14 13D/A DARE / Daré Bioscience, Inc. 326,243
2019-02-04 13D/A SELB / Selecta Biosciences Inc 1,627,527 2,779,889
2018-12-21 13D/A FATE / Fate Therapeutics, Inc. 1,926,660
2018-05-03 13D/A SELB / Selecta Biosciences Inc 1,690,844 1,627,527
2018-04-12 13D/A PULM / Pulmatrix, Inc. 4,031,019 7,510,187
2018-02-07 13G KALA / KALA BIO, Inc. 1,890,913
2017-11-29 13D XFOR / X4 Pharmaceuticals, Inc. 1,868,957
2017-09-29 13D/A SELB / Selecta Biosciences Inc 1,987,468 1,690,844
2016-07-07 13D SELB / Selecta Biosciences Inc 1,987,468
2016-02-16 13D/A GNCA / Genocea Biosciences Inc 2,055,230 1,968,606
2016-02-16 13D/A TTOO / T2 Biosystems, Inc. 1,840,564 2,018,450
2016-02-16 13G/A OCUL / Ocular Therapeutix, Inc. 1,230,009
2015-09-10 13D/A TRVN / Trevena, Inc. 2,669,280
2015-06-25 13D PULM / Pulmatrix, Inc. 4,031,019
2015-05-22 13D LIFE / aTyr Pharma, Inc. 1,840,564
2015-05-22 13D TTOO / T2 Biosystems, Inc. 2,291,307 1,840,564
2015-05-14 13D/A GNCA / Genocea Biosciences Inc 2,055,230
2015-05-14 13D TTOO / T2 Biosystems, Inc. 2,374,571
2014-08-11 13G OCUL / Ocular Therapeutix, Inc. 2,530,009
2014-05-05 13D TRVN / Trevena, Inc. 3,811,682
2014-04-21 13D DARE / Daré Bioscience, Inc. 3,287,529
2014-02-14 13D BIND / BIND Therapeutics, Inc. 2,018,253
2014-02-14 13D GNCA / Genocea Biosciences Inc 2,128,678
2013-10-11 13D FATE / Fate Therapeutics, Inc. 2,473,186